Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

38.1%

8 terminated/withdrawn out of 21 trials

Success Rate

61.9%

-24.6% vs industry average

Late-Stage Pipeline

62%

13 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

13(61.9%)

Phase 1

6(28.6%)

Phase 2

2(9.5%)

21Total

Phase 3(13)

Phase 1(6)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT03060980Phase 3Terminated

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Role: lead

NCT01785771Phase 3Terminated

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Role: lead

NCT02638805Phase 3Completed

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Role: lead

NCT01455896Phase 3Completed

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Role: lead

NCT02641899Phase 1Completed

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Role: lead

NCT02650479Phase 1Completed

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Role: lead

NCT02320045Phase 1Completed

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

Role: lead

NCT01455870Phase 3Completed

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Role: lead

NCT02641990Phase 1Completed

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

Role: lead

NCT01455857Phase 3Completed

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Role: lead

NCT00044291Phase 3Completed

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Role: lead

NCT00943917Phase 2Completed

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT00010322Phase 3Terminated

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Role: lead

NCT01798264Phase 1Completed

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Role: lead

NCT01455909Phase 3Withdrawn

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

Role: lead

NCT01455883Phase 3Withdrawn

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

Role: lead

NCT01455922Phase 3Withdrawn

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

Role: lead

NCT00519792Phase 1Completed

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

Role: lead

NCT00267553Phase 3Terminated

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Role: lead

NCT00097045Phase 2Completed

Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C

Role: lead